Bio-Rad Laboratories Inc
$ 268.88
0.00%
24 Feb - close price
- Market Cap 6,628,170,000 USD
- Current Price $ 268.88
- High / Low $ 268.88 / 268.88
- Stock P/E N/A
- Book Value 241.72
- EPS -76.53
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.28 %
- 52 Week High 265.82
- 52 Week Low 225.29
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
N/A
Quarterly Earnings
| Dec 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-29 | 2023-10-26 | 2023-08-03 | 2023-05-04 | 2023-02-16 | 2022-10-27 |
| Reported EPS | None | 2.2894 | -25.567 | 23.3401 | -76.2629 | 13.4533 | 3.1 | 2.33 | 3 | 3.34 | 3.31 | 2.6 |
| Estimated EPS | None | None | None | None | None | 2.99 | 2.84 | 2.76 | 2.64 | 3.63 | 3.48 | 2.7 |
| Surprise | 0 | 0 | 0 | 0 | 0 | 10.4633 | 0.26 | -0.43 | 0.36 | -0.29 | -0.17 | -0.1 |
| Surprise Percentage | None% | None% | None% | None% | None% | 349.9431% | 9.1549% | -15.5797% | 13.6364% | -7.989% | -4.8851% | -3.7037% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO-B
2026-02-23 12:36:00
This article provides an algorithmic analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The report also mentions the availability of real-time AI-generated signals and institutional-grade analysis for subscribers.
2026-02-13 06:27:54
Bio-Rad Labs B reported fourth-quarter EPS of $2.51, missing analyst estimates by $0.19, despite revenue of $693.2 million topping the consensus estimate of $693.17 million. The stock has experienced negative EPS revisions recently but maintains a "good performance" financial health score according to InvestingPro. Over the past year, the stock is up 5.10%, though it has declined by 5.98% in the last three months.
2026-02-13 00:27:54
Bio-Rad Laboratories (NYSE:BIO.B) recently announced its quarterly earnings, reporting $2.51 EPS. Despite a negative net margin of 26.43%, the company achieved a positive return on equity of 4.19%. Shares remained flat at $295.05 on minimal trading volume, indicating strong liquidity and low leverage with a market cap of $7.96 billion.
2026-02-07 22:30:40
Bio-Rad Laboratories B (BIO.B.US) is scheduled to release its earnings report after the market close on February 13. The company previously reported Q3 2025 revenue of $653 million with a net loss of $342 million and Q4 2024 revenue of $668 million with a net loss of $716 million. Investors are encouraged to stay tuned for the upcoming report and subsequent earnings call.
2026-02-07 10:57:55
Allianz Asset Management GmbH increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.7% in Q3, now owning 66,549 shares valued at $18.66 million. Institutional investors collectively own 65.24% of the company, which has a market cap of $8.15 billion and a mixed analyst rating with a consensus "Hold" and a $358.50 price target. The company faces a negative trailing P/E of -12.43 but shows strong liquidity with a current ratio of 5.44.
2026-02-02 22:58:09
Veritas Asset Management LLP reduced its stake in Bio-Rad Laboratories, Inc. by 2.2% in Q3, holding 844,039 shares valued at $236.66 million. This position represents 2.5% of Veritas's portfolio and 3.12% of Bio-Rad Laboratories. Wall Street analysts currently give Bio-Rad Laboratories a "Hold" rating with an average target price of $358.50, and institutional investors own 65.24% of the stock.
